The earnings call presented strong revenue growth, improvements in adjusted EBITDA, and significant free cash flow improvement, highlighting the company's operational resilience and strategic execution. However, challenges such as negative free cash flow due to a one-time payment, phasing impacts in specific segments, and the financial impact of the Inflation Reduction Act were noted. Despite these challenges, the positive aspects of growth and efficiency improvements outweigh the negatives.

Company Guidance

In the first quarter of 2025, Grifols reported a robust financial performance, achieving a revenue of EUR1.786 billion, reflecting a 7.4% increase on a constant currency basis, and a 10% rise on a like-for-like basis. Adjusted EBITDA reached EUR400 million, marking a 14.2% improvement, and nearly 22% on a like-for-like basis. Despite a negative free cash flow of EUR44 million due to a payment to ImmunoTek, the company noted a year-on-year improvement of over EUR200 million. Grifols attributed this success to strong growth in their immunoglobulin franchise, with IV and subcutaneous IG growing impressively, particularly subcutaneous IG, which surged by 91% at constant currency. The company anticipates ongoing revenue growth, supported by improved performances in rabies, albumin, and alpha-1 franchises, alongside initiatives to lower costs and enhance operational efficiencies. Grifols remains committed to further deleveraging its balance sheet and achieving sustained revenue, profitability, and free cash flow growth throughout the year.

Strong Revenue Growth

Revenue reached EUR1.786 billion, a 7.4% increase on a constant currency basis. On a like-for-like basis, revenue increased by 10%.

Adjusted EBITDA Improvement

Adjusted EBITDA for the quarter reached EUR400 million, an improvement of 14.2% at constant currency. Like-for-like, it grew by close to 22%.

Impressive Free Cash Flow Improvement

Free cash flow for the quarter improved by over EUR200 million year-on-year, despite being negative EUR44 million due to a EUR79 million payment to ImmunoTek.

Immunoglobulin Segment Growth

The immunoglobulin franchise achieved 17.5% growth in revenue at constant currency, led by both IV and subcutaneous IG.

Operational Efficiency Gains

Continued improvements in cost per liter and yield, along with a focus on operational leverage improvement.

Grifols SA (GRFS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GRFS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.27 / -	0.084	―	―	―
Jul 29, 2025	2025 (Q2)	0.23 / 0.20	0.024	712.50% (+0.17)
May 12, 2025	2025 (Q1)	0.15 / 0.09	0.034	170.59% (+0.06)
Feb 26, 2025	2024 (Q4)	0.23 / 0.11	0.089	21.35% (+0.02)
Nov 07, 2024	2024 (Q3)	0.22 / 0.08	0.15	-44.00% (-0.07)
Jul 30, 2024	2024 (Q2)	0.15 / 0.02	0.165	-85.45% (-0.14)
May 14, 2024	2024 (Q1)	0.11 / 0.03	0.044	-22.73% (>-0.01)
Feb 29, 2024	2023 (Q4)	0.22 / 0.09	0.1	-11.00% (-0.01)
Nov 02, 2023	2023 (Q3)	0.20 / 0.15	0.213	-29.58% (-0.06)
Jul 27, 2023	2023 (Q2)	0.20 / 0.17	0.132	25.00% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GRFS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$9.96	$10.36	+4.02%
May 12, 2025	$7.00	$7.63	+9.00%
Feb 26, 2025	$7.28	$7.83	+7.55%
Nov 07, 2024	$8.93	$9.37	+4.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Grifols SA (GRFS) report earnings?

Grifols SA (GRFS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Grifols SA (GRFS) earnings time?

Grifols SA (GRFS) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GRFS EPS forecast?

GRFS EPS forecast for the fiscal quarter 2025 (Q3) is 0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing